Genmab A/S Sponsored ADR $GMAB Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. raised its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 1.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 749,603 shares of the company’s stock after purchasing an additional 13,277 shares during the period. Envestnet Asset Management Inc.’s holdings in Genmab A/S were worth $15,487,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of GMAB. Rhumbline Advisers grew its stake in shares of Genmab A/S by 3.2% during the first quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock worth $332,000 after purchasing an additional 532 shares in the last quarter. CWM LLC increased its stake in Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after purchasing an additional 603 shares during the last quarter. Yousif Capital Management LLC increased its stake in Genmab A/S by 7.8% in the second quarter. Yousif Capital Management LLC now owns 10,943 shares of the company’s stock valued at $226,000 after purchasing an additional 790 shares during the last quarter. Park Avenue Securities LLC raised its holdings in Genmab A/S by 5.9% during the second quarter. Park Avenue Securities LLC now owns 14,940 shares of the company’s stock worth $309,000 after purchasing an additional 832 shares in the last quarter. Finally, Gallacher Capital Management LLC lifted its position in shares of Genmab A/S by 6.8% during the 1st quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company’s stock worth $281,000 after buying an additional 915 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $28.84 on Friday. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $33.65. The stock has a market capitalization of $18.52 billion, a price-to-earnings ratio of 14.49, a PEG ratio of 1.62 and a beta of 0.96. The company has a 50-day simple moving average of $29.53 and a 200-day simple moving average of $24.37.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The firm had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $5.77 billion. As a group, research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GMAB has been the topic of a number of recent analyst reports. Truist Financial set a $48.00 target price on shares of Genmab A/S in a research report on Thursday. Wall Street Zen lowered Genmab A/S from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 18th. HC Wainwright reiterated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Finally, Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.